Expected Weight Loss on Tirzepatide

Realistic weight-loss expectations on tirzepatide are best anchored to actual clinical trial data rather than marketing claims. Here's what the SURMOUNT-1 trial showed, what to expect week by week, and the factors that determine where in the range you'll fall.

The headline numbers from SURMOUNT-1

The SURMOUNT-1 trial (NEJM 2022) is the pivotal phase 3 study that supported Zepbound's FDA approval for chronic weight management. It enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, but without diabetes. Results at 72 weeks (about 17 months):

• Tirzepatide 15 mg: Mean 20.9% body weight loss
• Tirzepatide 10 mg: Mean 19.5% body weight loss
• Tirzepatide 5 mg: Mean 15.0% body weight loss
• Placebo: Mean 3.1% body weight loss

Translated to a 220-pound starting weight, those mean losses would represent approximately 46, 43, and 33 pounds for the three doses.

What proportion of patients achieve meaningful weight loss?

• ≥5% weight loss: 91% on 15 mg, 89% on 10 mg, 85% on 5 mg, 35% on placebo
• ≥10% weight loss: 84% on 15 mg, 78% on 10 mg, 69% on 5 mg, 19% on placebo
• ≥15% weight loss: 71% on 15 mg, 60% on 10 mg, 50% on 5 mg, 9% on placebo
• ≥20% weight loss: 57% on 15 mg, 41% on 10 mg, 30% on 5 mg, 3% on placebo

Most patients on the maximum dose lose at least 15% of body weight, with more than half losing 20% or more.

Week-by-week weight loss pattern

• Weeks 1–4 (2.5 mg starting dose): Most patients lose 2–6 pounds. The starting dose is acclimation; not maximum effect.
• Weeks 5–12 (5 mg → 10 mg titration): Weight loss accelerates to typically 1–2 pounds per week.
• Weeks 13–24 (10–15 mg maintenance): Continued steady weight loss at roughly 1–2 pounds weekly, gradually slowing.
• Months 6–9: Rate of loss naturally slows as the body approaches a new equilibrium. Total loss typically 15–20% by month 9.
• Months 9–18: Continued gradual loss in many patients. Final SURMOUNT-1 results were at 72 weeks (17 months).

What factors affect individual results?

• Starting BMI: Higher starting BMI often produces larger absolute weight loss
• Diabetes status: Adults with type 2 diabetes typically lose somewhat less weight than non-diabetic adults (SURMOUNT-2 mean: 15.7% on 15 mg)
• Final dose tolerated: Patients reaching 15 mg lose more on average than those maintained at 5 mg
• Adherence: Missed doses or treatment interruptions reduce total weight loss
• Lifestyle integration: Patients combining tirzepatide with dietary changes and exercise typically exceed the trial mean
• Sex: Women have shown somewhat greater percentage weight loss than men in subgroup analyses

What about weight regain after stopping?

The SURMOUNT-4 trial directly addressed this. Participants completed 36 weeks of open-label tirzepatide treatment, then were randomized to continue tirzepatide or switch to placebo for an additional 52 weeks. The continued-tirzepatide group maintained and modestly extended their weight loss; the placebo-switch group regained substantial weight over the following year.

The clinical implication: tirzepatide functions like medications for other chronic conditions — sustained benefit requires sustained therapy.

Setting realistic expectations

• Expect a slow first month — the 2.5 mg starting dose is acclimation
• Expect 1–2 pounds per week during months 2–6
• Expect 15–20% body weight loss by month 9–12 on the higher doses
• Expect plateaus — they're normal and don't mean the medication has stopped working
• Plan for long-term therapy if your goal is sustained weight loss

For physician-led programs that include progress tracking, Care360 coaching, and dose adjustment as appropriate, see our May 2026 ranking of tirzepatide telehealth providers.

Frequently Asked Questions